 | Up a level |
Pabst, Thomas; Vey, Norbert; Adès, Lionel; Bacher, Ulrike; Bargetzi, Mario; Fung, Samson; Gaidano, Gianluca; Gandini, Domenica; Hultberg, Anna; Johnson, Amy; Ma, Xuewen; Müller, Rouven; Nottage, Kerri; Papayannidis, Cristina; Recher, Christian; Riether, Carsten; Shah, Priya; Tryon, Jeffrey; Xiu, Liang and Ochsenbein, Adrian F (2023). Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica - the hematology journal, 108(7), pp. 1793-1802. Ferrata-Storti Foundation 10.3324/haematol.2022.281563
Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Ulrike; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Francisco, David; Bruggmann, Remy; van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; de Haard, Hans; Leupin, Nicolas; ... (2020). Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nature medicine, 26(9), pp. 1459-1467. Springer Nature 10.1038/s41591-020-0910-8
Riether, Carsten; Pabst, Thomas; Höpner, Sabine; Bacher, Vera; Hinterbrandner, Magdalena; Banz, Yara; Müller, Rouven; Manz, Markus G.; Gharib, Walid H.; Ferreira, David; Bruggmann, Remy; Van Rompaey, Luc; Moshir, Mahan; Delahaye, Tim; Gandini, Domenica; Erzeel, Ellen; Hultberg, Anna; Fung, Samson; De Haard, Hans; Leupin, Nicolas; ... (2 December 2018). 2680 Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial (Unpublished). In: ASCO 2018. 2. Dezember 2018.
